- Went public, Mar 2022
- Raised $36.9M funding round led by Oramed Pharmaceuticals, Apr 2025
- Raised $26M funding round, Jun 2020
About
Alpha Tau is a medical device company that focuses on the development and commercialization of its Diffusing Alpha-emitters Radiation Therapy (DaRT) for the treatment of solid cancers.
The technology, which was developed at Tel Aviv University in 2003, enables a highly potent and conformal radiotherapy treatment using alpha-emitting atoms. Directly inserted into the tumor, the Alpha DaRT seeds release a high-energy dose over a range of several millimeters, enabling a focal alpha-radiation treatment that spares the surrounding healthy tissue.
In 2017, Alpha Tau started with its first-in-human study of locally advanced and recurrent SCC cancers of the skin and head and neck, the results of which were subsequently published in the prestigious International Journal of Radiation Oncology | Biology | Physics. Following these initial encouraging results, Alpha Tau substantially expanded its clinical evaluations in later trials to a much wider patient population. The supportive data from these first trials also led to the FDA granting Breakthrough Device Designation to the Alpha DaRT for the treatment of patients with SCC of the skin or oral cavity without curative standard of care. Later on, Alpha Tau also received FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM (glioblastoma multiforme).
Today, in partnership with a number of esteemed medical and educational institutions worldwide, Alpha Tau has commenced several clinical and pre-clinical studies which are presently ongoing, and is also currently evaluating other potential uses of the Alpha DaRT technology for indications such as breast, pancreas, lung, GBM and prostate cancers, as well as other applications such as combinations with immunotherapies.
Funding history · 6 rounds · $201.9M total
Q&A
- What is Alpha Tau Medical's primary focus?
- Alpha Tau Medical is a medical device company focused on the development and commercialization of its Diffusing Alpha-emitters Radiation Therapy (DaRT) for the treatment of solid cancers.
- When did Alpha Tau Medical go public and on which exchange?
- Alpha Tau Medical went public on NASDAQ in March 2022, raising $90 million through a public offering.
- What was a significant funding round for Alpha Tau Medical in 2018?
- In September 2018, Alpha Tau Medical raised $29 million in a funding round with participation from OurCrowd.
- What was a recent funding event for Alpha Tau Medical?
- In April 2025, Alpha Tau Medical secured $36.9 million in a funding round led by.
- What is the current employee count for Alpha Tau Medical?
- Alpha Tau Medical has 106 employees, falling within the 51-200 employee bucket.
- What is Alpha Tau Medical's total funding raised to date?
- According to startupim data, Alpha Tau Medical has raised a total of $201.9 million.
- What is Alpha Tau Medical's market capitalization?
- Alpha Tau Medical has a market capitalization of $422,057,523.
- What is a recent regulatory milestone for Alpha Tau Medical's Alpha DaRT therapy?
- In February 2026, Alpha Tau Medical received regulatory marketing approval from Japan's Ministry of Health, Labour and Welfare for its Alpha DaRT cancer therapy for unresectable locally advanced or locally recurrent head and neck cancer.
- What is Alpha Tau Medical doing to expand its manufacturing capabilities?
- In October 2023, Alpha Tau Medical entered into a long-term lease for a standalone building in Hudson, New Hampshire, to establish its second U.S. manufacturing site, with manufacturing operations expected to begin within two years.
- What is Alpha Tau Medical's strategy for addressing pancreatic cancer?
- In September 2025, Alpha Tau Medical initiated a U.S. multi-center pilot study for its Alpha DaRT therapy combined with chemotherapy, targeting newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | alphatau.com |
|---|---|
| linkedin.com/company/10538741 | |
| facebook.com/AlphaTauMedical | |
| YouTube | youtube.com/channel/UCMmWvVwo1iEaQbncaIrK1PQ |
| Crunchbase | crunchbase.com/organization/althera-medical-ltd |
Identifiers & details
| Founded | 2016-1 |
|---|---|
| Employees (exact) | 106 |
| Offices | Lawrence |
| Market cap | $422.1M |
| Status reason | Public on NASDAQ on Mar, 2022; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2022-03 | $90.0M |